Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 280

1.

Intravesical seeding of upper urinary tract urothelial carcinoma cells during nephroureterectomy: an exploratory analysis from the THPMG trial.

Ito A, Shintaku I, Satoh M, Ioritani N, Tochigi T, Numata I, Namima T, Kambe K, Kyan A, Ueno S, Katoh S, Adachi H, Yamashita S, Yamaguchi T, Arai Y; Tohoku Urological EBM Study Group.

Jpn J Clin Oncol. 2013 Nov;43(11):1139-44. doi: 10.1093/jjco/hyt129. Epub 2013 Sep 4.

2.

Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial.

Ito A, Shintaku I, Satoh M, Ioritani N, Aizawa M, Tochigi T, Kawamura S, Aoki H, Numata I, Takeda A, Namiki S, Namima T, Ikeda Y, Kambe K, Kyan A, Ueno S, Orikasa K, Katoh S, Adachi H, Tokuyama S, Ishidoya S, Yamaguchi T, Arai Y.

J Clin Oncol. 2013 Apr 10;31(11):1422-7. doi: 10.1200/JCO.2012.45.2128. Epub 2013 Mar 4.

3.

The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: a multi-institutional study.

Tanaka N, Kikuchi E, Kanao K, Matsumoto K, Shirotake S, Kobayashi H, Miyazaki Y, Ide H, Obata J, Hoshino K, Hayakawa N, Kosaka T, Oyama M, Miyajima A, Momma T, Nakagawa K, Jinzaki M, Nakajima Y, Oya M.

Urol Oncol. 2014 Jan;32(1):48.e19-26. doi: 10.1016/j.urolonc.2013.07.003. Epub 2013 Sep 18.

PMID:
24055429
4.

[Effect of prophylactic intravesical instillation of pirarubicin to prevent recurrent bladder tumors following nephroureterectomy for upper urinary tract cancer].

Nagashima M, Araki A, Yanagisawa M, Komiya A, Takano T, Murakami T, Ikeda I.

Hinyokika Kiyo. 2013 Apr;59(4):213-6. Japanese.

5.

Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy?

Wu WJ, Ke HL, Yang YH, Li CC, Chou YH, Huang CH.

J Urol. 2010 Jan;183(1):56-61. doi: 10.1016/j.juro.2009.08.154. Epub .

PMID:
19913833
7.

Muscle-invasive bladder cancer developing after nephroureterectomy for upper urinary tract urothelial carcinoma.

Kim KH, You D, Jeong IG, Hong JH, Ahn H, Kim CS.

Urol Oncol. 2013 Nov;31(8):1643-9. doi: 10.1016/j.urolonc.2012.04.014. Epub 2012 May 15.

PMID:
22591745
8.

Independent prognostic factors for initial intravesical recurrence after laparoscopic nephroureterectomy for upper urinary tract urothelial carcinoma.

Liu Y, Lu J, Hong K, Huang Y, Ma L.

Urol Oncol. 2014 Feb;32(2):146-52. doi: 10.1016/j.urolonc.2013.02.018. Epub 2013 Apr 28.

PMID:
23628312
9.

The effect of intravesical chemotherapy in the prevention of intravesical recurrence after nephroureterectomy for upper tract urothelial carcinoma: a meta-analysis.

Yuan H, Mao X, Bai Y, Li H, Liu L, Pu C, Li J, Tang Y, Wei Q, Han P.

J Chemother. 2015 Aug;27(4):195-200. doi: 10.1179/1973947815Y.0000000034. Epub 2015 May 13. Review.

PMID:
25968487
10.

Prophylactic intravesical chemotherapy decreases bladder tumor recurrence after nephroureterectomy for primary upper tract urothelial carcinoma: A systematic review and meta-analysis.

Wu P, Zhu G, Wei D, Liu S, Walsh K, Li D, Harron U, Wang X, Ma H, Wan B, Sun L, Yang Z, Wang J.

J BUON. 2015 Sep-Oct;20(5):1229-38. Review.

PMID:
26537069
11.

Preoperative positive urine cytology is a risk factor for subsequent development of bladder cancer after nephroureterectomy in patients with upper urinary tract urothelial carcinoma.

Kobayashi Y, Saika T, Miyaji Y, Saegusa M, Arata R, Akebi N, Takenaka T, Manabe D, Nasu Y, Kumon H.

World J Urol. 2012 Apr;30(2):271-5. doi: 10.1007/s00345-011-0731-y. Epub 2011 Jul 30.

PMID:
21805177
12.

Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.

Milojevic B, Djokic M, Sipetic-Grujicic S, Grozdic Milojevic I, Vuksanovic A, Nikic P, Vukovic I, Djordjevic D, Bumbasirevic U, Tulic C.

Urol Oncol. 2013 Nov;31(8):1615-20. doi: 10.1016/j.urolonc.2012.03.004. Epub 2012 Apr 21.

PMID:
22521771
13.
15.

Positive voided urine cytology predicts worse pathological findings of nephroureterectomy specimens in patients with upper tract urothelial carcinoma: does selective ureteral cytology have an additional efficacy?

Sakano S, Inamoto T, Inoue R, Matsumoto H, Nagao K, Yamamoto Y, Azuma H, Matsuyama H.

Jpn J Clin Oncol. 2015 Oct;45(10):968-72. doi: 10.1093/jjco/hyv114. Epub 2015 Jul 30.

16.

Predictors of intravesical recurrence after radical nephroureterectomy for upper urinary tract urothelial carcinoma: an inflammation-based prognostic score.

Cho YH, Seo YH, Chung SJ, Hwang I, Yu HS, Kim SO, Jung SI, Kang TW, Kwon DD, Park K, Hwang JE, Heo SH, Kim GS, Hwang EC.

Korean J Urol. 2014 Jul;55(7):453-9. doi: 10.4111/kju.2014.55.7.453. Epub 2014 Jul 11.

17.

Tumour multifocality and grade predict intravesical recurrence after nephroureterectomy in patients with upper urinary tract urothelial carcinoma without a history of bladder cancer.

Narukawa T, Hara T, Arai E, Komiyama M, Kawahara T, Kanai Y, Fujimoto H.

Jpn J Clin Oncol. 2015 May;45(5):488-93. doi: 10.1093/jjco/hyv019. Epub 2015 Feb 12.

18.

Prophylactic intravesical chemotherapy to prevent bladder tumors after nephroureterectomy for primary upper urinary tract urothelial carcinomas: a systematic review and meta-analysis.

Fang D, Li XS, Xiong GY, Yao L, He ZS, Zhou LQ.

Urol Int. 2013;91(3):291-6. doi: 10.1159/000350508. Epub 2013 Aug 14. Review.

PMID:
23948770
19.
20.

Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial).

O'Brien T, Ray E, Singh R, Coker B, Beard R; British Association of Urological Surgeons Section of Oncology.

Eur Urol. 2011 Oct;60(4):703-10. doi: 10.1016/j.eururo.2011.05.064. Epub 2011 Jun 12.

PMID:
21684068
Items per page

Supplemental Content

Write to the Help Desk